Abbott (ABT) Director Credited 293 Units; Holdings 12,663
John G. Stratton, a director of Abbott Laboratories (ABT), had 293 stock-equivalent units credited on 09/30/2025 under a grantor trust that converts director fees into units that track Abbott share returns.
Rhea-AI Filing Summary
John G. Stratton, a director of Abbott Laboratories (ABT), had 293 stock-equivalent units credited on 09/30/2025 under a grantor trust that converts director fees into units that track Abbott share returns. The units are valued at $133.94 each in this filing and the reporting person’s total beneficial ownership after the transaction is reported as 12,663 shares or share equivalents. The filing explains these units are paid in cash generally at age 65 or upon retirement from the board and that the balance includes units from a dividend reinvestment feature. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Positive
- Director compensation converted to stock-equivalents aligns pay with shareholder returns
- Dividend reinvestment feature increased the balance of stock-equivalent units
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Equivalent Units | 293 | $133.94 | $39K |
Footnotes (2)
- F1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
- F2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
FAQ
What did John G. Stratton report on the Form 4 for ABT?
How were the 293 units acquired according to the filing?
What price is shown for the stock-equivalent units?
When will the stock-equivalent units be paid out?
Does the reported balance include dividends?
AI-generated analysis. How Rhea-AI works. Not financial advice.